Intratumoral Microdosing of Motolimod in HNSCC
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE2
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
GVAX Plus Checkpoint Blockade in Neuroblastoma
- Status
- TERMINATED
- Phase
- PHASE1
P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.
- Status
- TERMINATED
- Phase
- PHASE2
Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
- Status
- RECRUITING
- Phase
- PHASE2
Cabozantinib and Nivolumab for Carcinoid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
- Status
- COMPLETED
- Phase
- PHASE2
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2